and our conference believe you for XXXX long-term NASDAQ Jason. early what company everyone as XXXX we which We achieve for Thank a thank much has And the collectively first during quarterly positioned joining listed company. substantial call you, growth.
to the uplisting core and surrounding XX-months. the to January in life returns But NASDAQ specialty produce important which Enteris finance this stock those our to in business Capital clearly August our continues in past year been of of events common acquisition the the XXXX of healthcare are Market performance transformative BioPharma the solid While to XXXX. highlights sciences strong ongoing has
in discuss all each begin I everyone's health shortly, of but of will outbreak. I society the business. these The the global initiatives immune. coronavirus is I Covid-XX current detail resonate businesses must or feel crisis SWK virus is minds in unprecedented like all impacting in aspects topic not
situation the to halted work-related have we much company-wide safety measures as are as employees and by To travel. policy work-from-home possible a instituted day. the of of taking We and actively families, day impact their the mitigate well-being our and ensure
the largely from With the ability remotely, to impact. that operations SWK its daily believes insulated are work
healthcare on Unquestionably provide products hospitals having Covid-XX to the in a and is doctors companies that effect and sector. Everything patients services, far-reaching medical offices, facilities. and medications the
weather contact the we with believe visibility. in on plan. are and positioned chain a outbreak business their began, Thus the management regular is been focused have Since initially recently the to monitoring on companies, we the and the on focused supply situation the portfolio a contingency We far, vigilantly our impact in businesses. more liquidity challenges individual team impacting portfolio particular disruptions
believe address reopen businesses needs. to and to these of companies to destruction as pull While much doctors' in demand be demand this some to some rebound versus see We expect do we patient choppiness offices will as of business poised strengths. hospitals many
subscription within test protecting is called the [Indiscernible] Diagnostic is We testing strong of to diagnostic DxTerity the a KEEP which case important on Example with focus SME lifestyle system. property developing that is enterprise commercial demands AMERICA Covid-XX believe investing healthcare this this due medium service companies small, products WORKING. offer investor through
number in raise capital in we portfolio over a past the February. portfolio update companies XX-months disclosed of as successful Additionally, our disclosed publicly have our
SWK availability of remains not revolver. balance in well million companies our investment leveraged cash business Unlike heavily position. positive of cash development SWK's and and by capitalized hand the plan, $XX liquidity on net our sheet between past is illustrated with
identifying prudently Given capital remain stress put partner this, also work. we unprecedented prepared and to our companies support during importantly to this our time of to actively opportunities
compelling Specifically investment healthcare the otherwise offering probably be brought will small coronavirus lean undoubtedly should on unprecedented thinking dislocation front, companies' opportunities strong need capital. that on product by outbreak as in of create
compliance the of through XXb-XX as XXXX. circumstances under our a model. Exchange $X the of This XXXX. on company's program response Board programs dictate. expire business stock Holdings in and of on the will time February XXbX-X Directors price, XXth, stock with Rule of million to September It Act expired XX, additional In has continue from to program time authorized about plan the Securities trading dislocation common to evaluate is our to repurchase replaces that ideally stock to XXXX suited SWK repurchase
say closing continue outbreak some these In points, businesses fair to coronavirus is impact it for that on to will time.
structured However, and will the allow we to us potentially withstand position they compelling certainly us the price near-term difficulties when believe focus arise opportunities subside. for SWK
our unique stakes. future we to dilution allow monetize SWK, flow to solutions new no to cash those provide partners financing with equity their For that
and on investments, million substantial $XX their and direct just industry. offerings debt of range in the healthcare and include certain million first in mixed services transactions embedded to market to financing, We which Our acquisition. $X dynamics product growth focus
royalties million to $XXX.X June XXth yield effective totaled of December GAAP partners XXth, million $XXX.X That XX of royalties million as XXst, XXst, XXXX. $XXX.X of and a with XX.X%. compares As as SWK's favorably $XXX.X of back million portfolio December as of XXXX, and December across credit structured approximately by
our per asset as [Indiscernible] value for assets Enteris. specialty XXXX share of of XXst, XXXX. December $XX.XX book $XX.XX to and share segment tangible which value SWK deferred net finance recorded also our book of XXst, the After to tax a per $XX.XX value compared of December the reported eliminates
quarter quarter was fourth of $X.XX results. $X.X GAAP SWK's increasing specialty and by million million share revenue income or fourth $X.XX is revenue driven strong adjusted or million income with SWK's per share. diluted non-GAAP per $X.X net net year-over-year consolidated finance our XX% diluted outstanding $X.X
expected a non-cash amortization that income The the write-down income non-GAAP impacted by related net royalty for tax. from periods and to of amortization Our items income income benefit benefit of mark-to-market net positions results to $X.X a lowering million and the including equity from asset. intangibles. our of $X.X intangible Enteris and due million asset adjusted $X.X tax million was in also Enteris accrual, related changes core
million revenue, XX% year-over-year with an the reported in [$XX.X SWK XXXX, results. driving increase finance specialty For division $XX.X million]
adjusted $XX.X income intangibles consolidated or was and diluted XXXX income a SWK million, net Enteris share. from XXXX million rules. amortization $X results SWK was $XX.X income of and $X.XX non-GAAP GAAP $X.X or million tax related diluted share benefit per per were by $X.XX net impacted million,
with $X.XX the for Excluding and per income XXXX of specialty operating million, fourth results income of net of non-GAAP $X.X for the per business of XXXX. diluted share that adjusted BioPharma $XX.X adjusted acquisition, the quarter generated diluted and net associated Enteris financed share million, or non-GAAP costs core or $X.XX
of additional specialty agreements. existing active was million trend quarter punctuated SWK book XX.X% specialty approximately fourth like achieved to during segment results finance on continued was by XXXX credit tangible return with aggregate strong an adjusted that also capped segment I'd pursuant without strong to their first SWK The for an leverage. $XX with capital across through and deployment million year deploying during finance into this has value. a the partners the The XXXX Enteris. deploying $X.X quarter note
As as primary driver business announcing earlier, our anticipating for we transactions this growth additional SWK. noted year remains core the
footing working in results, XXXX XXXX hard to on our business recent strong As by despite and momentum maintain finance evidenced these event. in specialty our
note to like Enteris the share I amortization. a quick related intangibles on
acquisition, milestone under we we in near the expect agreement term existing term. the medium do for announcements receive to As the substantial payment noted in license to the
will As timeframe. the result over this, expected tangibles in accounting inflated amortizing a life SWK be receipt of GAAP
to them with shareholders. Going forward, strategy we for expect two-pronged value to build executing our
driving healthcare business offer traditional attractive expanding through a transactions beyond of all, synergistic and for shareholders. First valuations specialty capable returns of both upside optionality finance would our
efforts to and bringing shareholder enhancing field NASDAQ of larger serve The this Capital to and uplisting broadening visibility our a NASDAQ plan base in as SWK our by company BioPharma. centerpiece These business the in the our maximizing plan we SWK's trade and investment our will investors is are to enhance stock second stock new long-term Market to position liquidity of as SWK. The value. of shareholder publicly the execute move traded and drive concerns in Enteris expect we our
and milestones license between million Cara And formulation seller to royalty August in proprietary license Peptelligence. XXXX, was in August non-exclusive share company its with the SWK upfront XXXX. KORSUVA which SWK with agreement, XXth, oral offering the Peptelligence $XX.X Enteris terms agreed executed the that drug proprietary innovative In the Cara the of paid subsidiary its on proceeds, oral a operates and use license Therapeutic and agreement deal wholly of drug biotech candidate. another solution technology, is as now Enteris And Enteris a which development formulation drug utilizing delivery oral for owned to
potential. manufacturing rough full generating realize Revenue classic development platform Enteris is technology, proven capabilities, to is with believe yet we economic pipeline and the diamond a internal in that a its
as pretty $XX.X its strong reflected licensing technology specialty approximately we Similar Enteris acquisition. were licensing books tablet from had exceeding Our based Enteris future close. in returns revenue its derives segment, now work Enteris believe not that vision with at time of million evaluation economics XXXX on formulations total XXXX and partnerships to and and the growth currently consisting development of significant accelerate trial well a a is to royalties provide with milestone revenues for financed capital has potential and $XXX,XXX and resources as licenses Enteris' clinical to which realized of SWK current that manufacturing. royalty
underway to as the for expansion The Enteris XXXX expect in be in positioned completed we the be future. XXXX. should company capabilities facilities year the in manufacturing an Enteris majority for investment and We
bolsters regulatory team this licensing year, Dr. business unmatched commercialization. to partnership Enteris' drug and with that tasked external Medical programs advancing Enteris new In working an Enteris' Chief and Peptelligence Officer of key to with Enteris development opportunities development, executive Gary work hired with are leverage to business company's efforts. the to is team future. industry We Shangold, the augment veteran its platform, management a Gary develop most and February has with new importantly been internal experience biopharma development in and which and blend
including Peptelligence has drug executed candidates out three numerous in validated technology multiple clinical trials already spanning licensing been agreements.
license an received to last stock advance December upfront of Enteris is of is a announcement fee announced derisking severe and Phase top-line oral about data event disease. results in X Enteris. $X agreement on to second the from August this cash chronic expected acquisition Phase pruritus moderate fact, intend significant liver Cara that Cara year. in described is will dose by a half with announced and year, Cara of Top-line our dermatitis treatment and trials a ranging dose which with in opinion is kidney Cara entitled currently atopic patients chronic is for XXXX. program trial they X In positive in million tried be trial trial KORSUVA Phase to clinical royalties, In disease, previously, to future from Oral Cara Cara. the in undisclosed separate The KORSUVA X milestones the it for and evaluating studies. SWK and our shared three in
our point continued fiscal the SWK. is that XXXX efforts to their reflection thank our to undertaken. growth SWK wills from I'd this for evolve initiatives by Holdings. in of benefiting In year team. and at stakeholders made have support we employees dedication was forward And like our All the and loyalty model a clear look SWK for and as been their conclusion, of possible we our
to With your questions. call that I'll now open the
